Transcript levels of ten-eleven translocation type 1-3 in cervical cancer and non-cancerous cervical tissues

Bronowicka‑Kłys,Dorota  Ewa; Roszak,Andrzej; Pawlik,Piotr; Sajdak,Stefan; Sowińska,Anna; Jagodziński,Paweł  Piotr

doi:10.3892/ol.2017.5930

Transcript levels of ten-eleven translocation type 1-3 in cervical cancer and non-cancerous cervical tissues

Authors:
- Dorota Ewa Bronowicka‑Kłys
- Andrzej Roszak
- Piotr Pawlik
- Stefan Sajdak
- Anna Sowińska
- Paweł Piotr Jagodziński
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Poznań 60‑781, Poland, Department of Radiotherapy and Gynecological Oncology, Greater Poland Cancer Center, Poznań 61‑866, Poland, Division of Gynecological Surgery, Poznań University of Medical Sciences, Poznań 60‑535, Poland, Department of Computer Science and Statistics, Poznań University of Medical Sciences, Poznań 60‑529, Poland
Published online on: March 28, 2017 https://doi.org/10.3892/ol.2017.5930
Pages: 3921-3927

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Decreased expression of ten-eleven translocation (TET1, TET2 and TET3) proteins has been reported in various types of cancer. However, the expression levels of TET proteins in cervical cancer (CC) remain to be elucidated. The present study determined the levels of TET1, TET2 and TET3 transcripts in cancerous (n=80) and non‑cancerous cervical tissues (n=41). The results revealed a significant reduction in TET1 transcripts (P=0.0000001) in cervical tissue samples from patients with primary CC compared with samples from control patients. Significantly decreased TET1 transcript levels, as compared to non‑cancerous cervical tissues, were also observed in tissue samples with the following characteristics: Stage I (P=0.016), II (P<0.0001), III (P=0.00007) and grade of differentiation G1 (P=0.026), G2 (P=0.00006), G3 (P=0.0007) and Gx (P=0.0004) and squamous histological type (P<0.00001). TET1 transcript levels were significantly lower in patients aged 45‑60 years (P=0.0002) and patients age >60 years (P=0.003), as compared with non‑cancerous cervical tissues. TET2 transcript levels were lower in cervical cancer tissues classified as stage II (P=0.043) and TET3 transcript levels were lower in stage III samples (P=0.010), tissue samples with a grade of differentiation of G3 (P=0.025) and tissue with squamous type histology (P=0.047), all compared with non‑cancerous cervical tissues. The present study demonstrated a significantly reduced level of TET1 transcripts in cancerous cervical tissues, as compared with non‑cancerous tissues. Furthermore, decreased TET1‑3 transcript levels were identified when patients with CC were stratified by clinicopathological variables, as compared with non-cancerous cervical tissues.

View Figures

View References

1	Deręgowska J: Women with breast cancer in the network of social support-a quantitative context. Nowiny Lekarskie. 81:203–213. 2012.
2	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive MicroRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
4	Ibeanu OA: Molecular pathogenesis of cervical cancer. Cancer Biol Ther. 11:295–306. 2011. View Article : Google Scholar : PubMed/NCBI
5	Asih TS, Lenhart S, Wise S, Aryati L, Adi-Kusumo F, Hardianti Ms and Forde J: The dynamics of Hpv infection and cervical cancer cells. Bull Math Biol. 78:4–20. 2016. View Article : Google Scholar : PubMed/NCBI
6	Jiménez-Wences H, Peralta-Zaragoza O and Fernández-Tilapa G: Human papilloma virus, DNA methylation and microRNA expression in cervical cancer (Review). Oncol Rep. 31:2467–2476. 2014.PubMed/NCBI
7	Faridi R, Zahra A, Khan K and Idrees M: Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J. 8:2692011. View Article : Google Scholar : PubMed/NCBI
8	Fang J, Zhang H and Jin S: Epigenetics and cervical cancer: From pathogenesis to therapy. Tumour Biol. 35:5083–5093. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhang X, Zhang L, Tian C, Yang L and Wang Z: Genetic variants and risk of cervical cancer: Epidemiological evidence, meta-analysis and research review. BJOG. 121:664–674. 2014. View Article : Google Scholar : PubMed/NCBI
10	Li D, Guo B, Wu H, Tan L and Lu Q: TET family of dioxygenases: crucial roles and underlying mechanisms. Cytogenet Genome Res. 146:171–180. 2015. View Article : Google Scholar : PubMed/NCBI
11	Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, et al: Genetic characterization of TET1, TET2 and TET3 alterations in myeloid malignancies. Blood. 114:144–147. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC and Zhang Y: Role of tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI
13	Rawłuszko-Wieczorek AA, Siera A, Horbacka K, Horst N, Krokowicz P and Jagodziński PP: Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer. J Cancer Res Clin Oncol. 141:1379–1392. 2015. View Article : Google Scholar : PubMed/NCBI
14	Rawłuszko-Wieczorek AA, Siera A and Jagodziński PP: TET proteins in cancer: Current ‘state of the art’. Crit Rev Oncol Hematol. 96:425–436. 2015. View Article : Google Scholar : PubMed/NCBI
15	Saavedra KP, Brebi PM and Roa JC: Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics. 4:132012. View Article : Google Scholar : PubMed/NCBI
16	Głowacki S and Błasiak J: Role of 5-hydroxymethylcytosine and TET proteins in epigenetic regulation of gene expression. Postepy Biochem. 59:64–69. 2013.(In Polish). PubMed/NCBI
17	Frycz BA, Murawa D, Borejsza-Wysocki M, Marciniak R, Murawa P, Drews M, Kołodziejczak A, Tomela K and Jagodziński PP: Decreased expression of ten-eleven translocation 1 protein is associated with some clinicopathological features in gastric cancer. Biomed Pharmacother. 68:209–212. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H and Koike K: Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103:670–676. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, Chu CS, Jeng YM, Chen YT, Lin FM, et al: TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013. View Article : Google Scholar : PubMed/NCBI
21	Müller T, Gessi M, Waha A, Isselstein LJ, Luxen D, Freihoff D, Freihoff J, Becker A, Simon M, Hammes J, et al: Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol. 181:675–683. 2012. View Article : Google Scholar : PubMed/NCBI
22	Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, Yang Z, Wu L, Xia F, Bie P, et al: Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One. 8:e628282013. View Article : Google Scholar : PubMed/NCBI
23	Afanas'ev I: Mechanisms of superoxide signaling in epigenetic processes: Relation to aging and cancer. Aging Dis. 6:216–227. 2015. View Article : Google Scholar : PubMed/NCBI
24	Fan M, He X and Xu X: Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells. Mol Med Rep. 12:4837–4842. 2015.PubMed/NCBI
25	Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009. View Article : Google Scholar : PubMed/NCBI
26	Guz J, Jurgowiak M and Oliński R: Oxidation and deamination of nucleobases as an epigenetic tool. Postepy Hig Med Dosw (Online). 66:275–286. 2012.(In Polish). View Article : Google Scholar : PubMed/NCBI
27	Du C, Kurabe N, Matsushima Y, Suzuki M, Kahyo T, Ohnishi I, Tanioka F, Tajima S, Goto M, Yamada H, et al: Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer. Gastric Cancer. 18:516–525. 2015. View Article : Google Scholar : PubMed/NCBI
28	Böcker W: WHO classification of breast tumors and tumors of the female genital organs: Pathology and genetics. Verh Dtsch Ges Pathol. 86:116–119. 2002.(In German). PubMed/NCBI
29	Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
30	He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, et al: Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 333:1303–1307. 2011. View Article : Google Scholar : PubMed/NCBI
31	Liu L, Mao SQ, Ray C, Zhang Y, Bell FT, Ng SF, Xu GL and Li X: Differential regulation of genomic imprinting by TET proteins in embryonic stem cells. Stem Cell Res. 15:435–443. 2015. View Article : Google Scholar : PubMed/NCBI
32	An J, González-Avalos E, Chawla A, Jeong M, López-Moyado IF, Li W, Goodell MA, Chavez L, Ko M and Rao A: Acute loss of TET function results in aggressive myeloid cancer in mice. Nat Commun. 6:100712015. View Article : Google Scholar : PubMed/NCBI